E-MTAB-2122 - Transcription profiling by array of KMS12BM and H929 myeloma cells treated in vitro with either I-BET151 or vehicle
Last updated on 21 December 2013, released on 22 December 2013
KMS12BM and H929 myeloma cells were treated in vitro with either I-BET151 1uM or vehicle (DMSO) for 6 hours (n=3 independent experiments for each cell line). Total RNA was extracted from H929 and KMS12BM cells using the RNeasy Mini kit (Qiagen). Genomic DNA contamination was eliminated using columns (Qiagen) and DNAase digestion. The extracted RNA was quantified in a Nanodrop, while purity and integrity was confirmed on an Agilent 2100 Bioanalyser with RNA Nano Chips. cDNA was produced from 150ng total RNA input, using the Ambion WT Expression Kit. The cDNA was then fragmented and labelled using the GeneChip WT Terminal Labelling Kit (Affymetrix) and hybridised on Human Gene ST1.0 Arrays (Affymetrix) on a GeneChip Fluidics Station 450. The arrays were scanned in a GeneChip Scanner 3000 7G with autoloader.
transcription profiling by array, compound treatment design, in vitro
Potent anti-myeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Aristeidis Chaidos, Valentina Caputo, Katerina Gouvedenou, Binbin Liu, Ilaria Marigo, Suhail Chaudhry, Antonia Rotolo, David F. Tough, Nicholas N. Smithers, Anna K. Bassil, Trevor D. Chapman, Nicola R. Harker, Olena Barbash, Peter Tummino, Niam Al-Mahdi, Andrea C. Haynes, Leanne Cutler, BaoChau Le, Amin Rahemtulla, Irene Roberts, Maurits Kleijnen, Jason J. Witherington, Nigel J. Parr, Rab K. Prinjha, Anastasios Karadimitris.